Details for: SIMLANDI
Company: JAMP PHARMA CORPORATION
DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
---|---|---|---|---|---|
02523949 | SIMLANDI | ADALIMUMAB | 40 MG / 0.4 ML | SOLUTION | SUBCUTANEOUS |
02523957 | SIMLANDI | ADALIMUMAB | 40 MG / 0.4 ML | SOLUTION | SUBCUTANEOUS |
02523965 | SIMLANDI | ADALIMUMAB | 80 MG / 0.8 ML | SOLUTION | SUBCUTANEOUS |
Summary Reports
Consumer Information
This information was provided by the drug’s manufacturer when this drug product was approved for sale in Canada. It is designed for consumers and care givers. It is a summary of information about the drug and will not tell you everything about the drug. Contact your doctor or pharmacist if you have any questions about the drug.
What the medication is used for
Simlandi is a medicine that is used in:
- adults with rheumatoid arthritis, which is an inflammatory disease of the joints.
- adults with psoriatic arthritis, which is an inflammatory disease of the joints and skin.
- adults with ankylosing spondylitis, which is a form of arthritis.
- adults with Crohn’s disease, which is an inflammatory disease of the digestive tract.
- pediatrics with polyarticular juvenile idiopathic arthritis who are 2 years of age and older and require a full 40 mg dose based on body weight.
- adults with ulcerative colitis, which is an inflammatory disease of the bowel (colon).
- adults or adolescents (12 to 17 years of age, weighing ≥ 30 kg) with moderate to severe hidradenitis suppurativa (HS) who have not responded to antibiotics. HS is a painful, progressive, chronic inflammatory skin disease that causes nodules, abscesses, sinus tracts and fistulas under the breasts, underarms, buttocks and groin.
- adults with psoriasis, which is an inflammatory disease of the skin. The doctor prescribed Simlandi to reduce the signs and symptoms of your plaque psoriasis.
- adults with uveitis, which is an inflammatory disease of the eye.
- children (weighing ≥ 30 kg) with chronic non-infectious uveitis from 2 years of age with inflammation affecting the front of the eye.
Patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, hidradenitis suppurativa, psoriasis, or uveitis may be given other medicines for their disease before they are given Simlandi. If you have adult ulcerative colitis or you have Crohn’s disease, you will first be given other medicines. If you do not respond well enough to these medicines, you will be given Simlandi to reduce the signs and symptoms of your disease.
What it does
Simlandi is a recombinant fully human immunoglobulin G1 (IgG1) kappa monoclonal antibody (mAb) that specifically binds to tumor necrosis factor-α (TNF) and blocks its interaction with the p55 (TNFR1) and p75 (TNFR2) cell surface TNF receptors, thereby neutralizing the effect of TNF in inflammatory conditions. Simlandi is approved as a biosimilar to Humira (adalimumab).
People with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, hidradenitis suppurativa or psoriasis have too much of TNF-alpha in their bodies. The extra TNF-alpha in your/your child’s body can attack normal healthy body tissues and cause inflammation, especially in the tissues of your bones, cartilage, joints, digestive tract and skin. By binding to TNF-alpha, adalimumab decreases the inflammation process of these diseases.
Simlandi helps reduce the signs and symptoms of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and psoriatic arthritis (such as pain and swollen joints), may help improve your/your child’s ability to perform daily activities (such as getting dressed, walking and climbing stairs), and may help prevent further damage to your/your child’s bones and joints. In addition, Simlandi helps reduce the signs and symptoms of ankylosing spondylitis (back pain and morning stiffness), and adult Crohn’s disease or adult ulcerative colitis (abdominal pain and diarrhea).
Simlandi is also used to treat inflammatory lesions (nodules and abscesses) in adults and adolescents (12 to 17 years of age, weighing ≥ 30 kg) with hidradenitis suppurativa.
Simlandi also helps reduce the signs and symptoms ofpsoriasis (such as pain, itching and scaly patches on skin).
Simlandi helps control uveitis by reducing the risk of inflammation and loss of vision in adult and pediatric patients.
Simlandi, however, can also lower your/your child’s body’s ability to fight infections. Taking Simlandi can make you/your child more prone to getting infections or make any infection you/your child have worse.
When it should not be used
- you/your child has a known hypersensitivity (allergy) to adalimumab or any of its components. For a complete listing, (see 6 DOSAGE FORMS, COMPOSITION AND PACKAGING).
- you/your child has a severe infection such as sepsis (an infection of the blood), tuberculosis (a serious infection usually affecting the lungs) and opportunistic infections (infections that can occur when your defence system against infections is weak (See Serious Warnings and Precautions Box).
- you/your child has moderate to severe heart failure (when the heart does not pump normally (see Serious Warnings and Precautions Box).
What the medicinal ingredient is
Medicinal ingredient: Adalimumab
What the non-medicinal ingredients are
Non-medicinal ingredients: Polysorbate 80, sodium chloride, sucrose, and water for injection.
What dosage form it comes in
40 mg in 0.4 mL sterile solution (100 mg/mL) for injection (Pre-filled Syringe with needle guard and Autoinjector)
80 mg in 0.8 mL sterile solution (100 mg/mL) for subcutaneous injection (Pre-filled Syringe with needle guard)
Warnings and precautions
Serious Warnings and Precautions
- Allergic reactions: If you/your child develop a severe rash, swollen face or difficulty breathing while taking adalimumab, call your/your child’s doctor right away.
- Hepatoplenic T-cell lymphoma: Very rare reports of hepatosplenic T-cell lymphoma (HSTCL), a rare serious lymphoma that is often fatal, have been identified in patients treated with adalimumab. Most patients had also been treated with other medications for Crohn’s disease and the majority were in adolescent and young adult males. The link between HSTCL and adalimumab is not clear.
- Other cancers: There have been very rare cases of certain kinds of cancer in patients taking adalimumab or other TNF- blockers. Some patients receiving adalimumab have developed types of cancer called non-melanoma skin cancer. Tell your/your child’s doctor if you/your child have a bump or open sore that does not heal. People with more serious rheumatoid arthritis that have had the disease for a long time may have a higher than average risk of getting a kind of cancer that affects the lymph system, called lymphoma. If you/your child take adalimumab or other TNF-blockers, your/your child’s risk may increase. There have been cases of lymphoma and other cancers, including unusual types, in children, adolescents and young adults taking TNF-blocking agents, including adalimumab, which sometimes resulted in death. For children
- Lupus-like symptoms: Some patients have developed lupus-like symptoms that got better after their treatment was stopped. If you/your child have chest pains that do not go away, shortness of breath, joint pain or a rash on your/your child’s cheeks or arms that gets worse in the sun, call your/your child’s doctor right away. Your/your child’s doctor may decide to stop your/your child’s treatment.
- Nervous system diseases: There have been rare cases of disorders that affect the nervous system of people taking adalimumab or other TNF-blockers. Signs that you/your child could be experiencing a problem affecting your/your child’s nervous system include: numbness or tingling, problems with your/your child’s vision, weakness in your/your child’s legs, and dizziness.
- Serious infections: There have been rare cases where patients taking adalimumab or other TNF-blocking agents have developed serious infections. Some of these cases have been lifethreatening. Such infections include tuberculosis, infections caused by bacteria or fungi, and bacterial infections that have spread throughout the body (sepsis). Infection causes include tuberculosis, legionellosis (a serious form of bacterial pneumonia), listeriosis (an infection that usually develops after eating food contaminated by bacteria called listeria), and very rare cases of hepatitis B infection relapse.
- Blood problems: In some instances, patients treated with TNF-blocking agents may develop low blood counts, such as anemia (low red blood cells) or low platelets. If you/your child develop symptoms such as persistent fever, bleeding, or bruising, you should contact your/your child’s doctor right away
To help avoid side effects and ensure proper use, talk to your healthcare professional before you take Simlandi. Talk about any health conditions or problems you may have, including if:
- you are taking anakinra or abatacept (other biologic drugs);
- a surgery is planned for you in the near future;
- you suffer from congestive heart failure (see Do not use Simlandi if);
- you suffer from any form of cytopenia (a condition where you do not have enough blood cells);
- you have lasting fever, bruising, bleeding or paleness;
- you develop lupus-like symptoms (such as rash, fever, fatigue, headache, painful joints)
- you have a history of tuberculosis;
- you have a history of fungal infections;
- you have a history of hepatitis B (an infection of the liver)
- you have a history of cancer such as leukemia (a cancer of the blood);
- you have a history of lymphoma (a cancer affecting the white blood cells)
Other warnings you should know about:
If you/your child received Simlandi while pregnant, your/her baby may be at higher risk for getting an infection for up to approximately five months after the last dose of Simlandi received during pregnancy. It is important that you tell your/her baby's doctors and other healthcare professionals about your/her Simlandi use during pregnancy so they can decide when your/her baby should receive any vaccine.
BEFORE you/your child use Simlandi, talk to the doctor or pharmacist if:
- you/your child have or have had any kind of infection including an infection that is in only one place in your/your child’s body (such as an open cut or sore), or an infection that is in your/your child’s whole body (such as the flu). Having an infection could put you/your child at risk for serious side effects from Simlandi. If you are unsure, ask your/your child’s doctor.
- You/your child have a history of infections that keep coming back or other conditions that might increase your/your child’s risk of infections, including fungal infections.
- you/your child have ever had tuberculosis, or if you/your child have been in close contact with someone who has had tuberculosis. If you/your child develop any of the symptoms of tuberculosis (a dry cough that doesn't go away, weight loss, fever, night sweats) call your/your child’s doctor right away. Your/your child’s doctor will need to examine you/your child for tuberculosis and perform a skin test.
- you/your child resided or travelled to areas where there is a greater risk for certain kinds of infections such as tuberculosis, histoplasmosis, coccidioidomycosis, blastomycosis, or parasitic infections. These infections are caused by a bacteria or a fungus that can affect the lungs or other parts of your/your child’s body. If you/your child take Simlandi, these may become active or more severe. If you don’t know if you/your child have lived in or travelled to an area where these infections are common, ask your/your child’s doctor.
- you/your child have ever had liver injury or hepatitis B virus infection or are at risk of developing this infection. Signs and symptoms include the following: yellowing of the skin or eyes (jaundice), feeling of sickness, tiredness, loss of appetite, joint pain, fever, dark browncoloured urine, vomiting, and abdominal pain. If you/your child experience any of these signs and symptoms, contact your/your child’s doctor immediately. These symptoms may occur several months after starting therapy with Simlandi.
- you/your child experience any numbness or tingling or have ever had a disease that affects your/your child’s nervous system like multiple sclerosis or Guillain-Barrésyndrome.
- you/your child have or have had heart failure.
- you/your child are scheduled to have major surgery or dental procedures.
- you/your child are scheduled to be vaccinated for anything. It is recommended that pediatric patients, if possible, be brought up to date with all immunizations according to current guidelines before starting Simlandi.
- you/your child are taking other medicines for your/your child’s rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis, or other conditions. You/your child can take other medicines provided your/your child’s doctor has prescribed them or has told you it is acceptable that you/your child take them while you/your child are taking Simlandi. It is important that you tell your/your child’s doctor about any other medicines you/your child are taking for other conditions (for example, high blood pressure medicine) before you/your child start taking Simlandi.
- you are taking other medicines for your Crohn’s disease or other conditions. You can take other medicines provided your doctor has prescribed them or has told you it is acceptable that you take them while you are taking Simlandi. It is important that you tell the doctor about any other medicines you are taking for other conditions before you start taking Simlandi.
- you/your child are taking any over-the-counter drugs, herbal medicines and vitamin and mineral supplements.
- you/your child are pregnant or could become pregnant.
- you/your child are breast-feeding or plan to breast-feed.
If you are not sure or have any questions about any of this information, ask your/your child’s doctor.
Interactions with this medication
Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.
The following may interact with Simlandi:
Other TNF-blockers such as:
- etanercept (Enbrel® ),
- abatacept (Orencia® )
- anakinra (Kineret® )
- infliximab (Remicade® )
- certolizumab pegol ((Cimzia® )
- golimumab (Simponi® )
How to take Simlandi
Simlandi is administered by injection under the skin (by subcutaneous injection).
Proper use of this medication
Usual Dose:
Adults with Rheumatoid Arthritis, Psoriatic Arthritis or Ankylosing Spondylitis:
- The recommended dose is 40 mg administered every other week as a subcutaneous injection.
Adults with Crohn’s Disease or Ulcerative Colitis:
- The recommended induction dose is 160 mg at Week 0, followed by 80 mg at Week 2 administered by subcutaneous injection. The first dose of 160 mg can be given in one day (four 40 mg injections or two 80 mg injections) or split over two consecutive days (two 40 mg injections or one 80 mg injection each day). The second dose of 80 mg at Week 2 is given as two 40 mg injections or one 80 mg injection in one day.
- The recommended maintenance dose regimen is 40 mg every other week beginning at Week
Adults with Hidradenitis Suppurative:
- The recommended initial dose is 160 mg, followed by 80 mg two weeks later administered by subcutaneous injection. The first dose of 160 mg at Week 0 can be given in one day (four 40 mg injections or two 80 mg injections) or split over two consecutive days (two 40 mg injections or one 80 mg injection each day) or split over two consecutive days (two 40 mg injections or one 80 mg injection each day). The second dose of 80 mg at Week 2 is given as two 40 mg injections or one 80 mg injection in one day.
- The recommended maintenance dose regimen is 40 mg every week beginning four weeks after the initial dose.
Adults with Psoriasis or Uveitis:
- The recommended dose is an initial dose of 80 mg, followed by 40 mg given every other week starting one week after the initial dose administered by subcutaneous injection. The first dose of 80 mg can be given as two 40 mg injections or one 80 mg injection.
Adolescents, 12 to 17 years of age weighing > 30 kg, with Hidradenitis Suppurativa:
- The recommended initial dose is 80 mg administered by subcutaneous injection (two 40 mg injections or one 80 mg injection), followed by 40 mg every other week starting one week later. Depending on your/your child’s response, the doctor may increase the dose to 40 mg every week.
Polyarticular juvenile idiopathic arthritis, weighing > 30 kg:
- The recommended dose of SIMLANDI is 40 mg subcutaneously every other week. SIMLANDI is only available for children who require the full 40 mg dosage. The autoinjector and pre-filled syringe are not designed to deliver a portion of the 40 mg dose.
Pediatric uveitis, weighing > 30 kg:
- The recommended dose of SIMLANDI is 40 mg subcutaneously every other week. SIMLANDI is only available for children who require the full 40 mg dosage. The autoinjector and pre-filled syringe are not designed to deliver a portion of the 40 mg dose.
Overdose:
Missed Dose
If you/your child forget to give yourself/your child an injection, you/your child should inject the missed dose of Simlandi as soon as you/your child remember. Then administer the next dose as you would have on the originally scheduled date
Side effects and what to do about them
These are not all the possible side effects you may have when taking Simlandi.
Like all medicines, Simlandi can cause side effects. Most side effects are mild to moderate. However, some may be serious and require treatment. Tell your/your child’s doctor immediately if you/your child experience any of the following:
- severe rash, hives or other signs of allergic reaction
- swollen face, hands, feet
- trouble breathing, swallowing
- sudden weight gain; this is possibly indicative of new or worsening heart failure
- bruising or bleeding very easily, looking very pale; this could mean a blood problem such as low red blood cells (anemia) or low platelets (other cells found in the blood)
Tell the doctor as soon as possible if you/your child notice any of the following:
- signs of infection such as fever, fatigue, wounds, dental problems, burning on urination
- feeling weak or tired
- coughing
- tingling
- numbness
- double vision
- arm or leg weakness
- arm or leg pain, swelling or redness
- bump or open sore that does not heal
- red scaly patches or raised bumps that are filled with pus; this could be new or worsening hidradenitis suppurativa, new or worsening psoriasis or a skin infection
- alopecia (loss of hair)
- changes in the colour of the skin
- changes in the colour of your/your child’s urine (dark or red)
- worsening of the appearance of a scar
- night sweats
- weight loss
- pain in the abdomen or chest
Symptom / effect | Talk to your healthcare professional Only if severe | Talk to your healthcare professional In all cases | Stop taking drug and get immediate medical help |
---|---|---|---|
VERY COMMON | |||
Injection site reaction | ✔ | ||
COMMON | |||
Cough and cold symptoms, including sore throat | ✔ | ||
Headache | ✔ | ||
Rash | ✔ | ||
Nausea | ✔ | ✔ | |
Pneumonia | ✔ | ||
Fever | ✔ | ||
Abdominal pain | ✔ | ✔ | |
RARE | |||
Tuberculosis | ✔ | ✔ | |
Other serious infections | ✔ | ✔ | |
Nerve disorder | ✔ | ✔ | |
Appendicitis | ✔ | ✔ | |
Blood clots:abdominal pain, chest pain, leg or arm pain with redness and swelling | |||
Bladder infection | ✔ | ✔ | |
Bladder infection | ✔ | ✔ |
If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional
How to store
Store between 2 and 8ºC (in a refrigerator) in the original carton until ready to use. DO NOT FREEZE Simlandi. Protect from light. Refrigerated Simlandi remains stable until the expiration date printed on the Autoinjector or pre-filled syringe. Do not use beyond the expiration date.
When needed, for example when you/your child are travelling, a Simlandi Autoinjector or pre-filled syringe can be stored at room temperature (up to 25ºC/77ºF) for a single maximum period of 14 days.
Once taken out of the refrigerator for room temperature storage, a Simlandi Autoinjector or pre-filled syringe must be used within 14 days, even if it is put back in the refrigerator. If not used within 14 days, the Simlandi Autoinjector or pre-filled syringe must be discarded. You should record the date when the Simlandi autoinjector or pre-filled syringe is first removed from the refrigerator.
Care should be taken to avoid dropping or crushing the product as it contains a glass syringe.
Keep Simlandi and all other medicines out of the reach and sight of children.
Reporting side effects
You can report any suspected side effects associated with the use of health products to Health Canada by:
- Visiting the Web page on Adverse Reaction Reporting (https://www.canada.ca/en/healthcanada/services/drugs-health-products/medeffect-canada.html) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.
NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.
More information
If you want more information about Simlandi:
- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (https://www.canada.ca/en/health-canada/services/drugs-health-products/drugproducts/drugproduct-database.html , the manufacturer’s website [https://www.jamppharma.com], or by calling 1-866-399-9091 #2.
This leaflet was prepared by JAMP Pharma Corporation.
Last revised: January 5, 2022